JPRN-UMIN000026324已完成未知
A phase 2 study of bortezomib, lenalidomide and dexamethasone (VRD) following auto-PBSCT for untreated multiple myeloma. - OCHA-VRD
Ochanomizu Hematology Study Group0 个研究点目标入组 32 人开始时间: 2017年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patient who has hypersensitivity to the study drugs. 2.Patient who has Grade >= 2 peripheral neuropathy (NCI CTCAE ver.4). 3.Patient who has sufficient heart disorders. 4.Uncontrolled active infection. 5.HBs antigen positive and/or HCV positive. 6.Active advanced-stage cancer. 7.Female patient who is pregnant and/or breastfeeding. 8.Active gastrointestinal bleeding. 9.Past history of renal transplantation. 10.Past history of pulmonary embolism, myocardial infarction and cerebral infarction. 11.Past history of deep vein thrombosis, administration of anticoagulants and/or antiplatelet drugs. 12.Uncontrolled diabetes mellitus. 13.Serious psychiatric illness 14.Patient who is judged to be medically unfit by his/her physician.
研究者
相似试验
尚未招募
不适用
Phase II trial of bortezomib, lenalidomide, and dexamethasone in patiens with high-risk smoldering myelomaDiseases of the blood and blood-forming organs and certain disorders involving the immune mechanismKCT0006266Chonnam National University Hospital Hwasun Hospital21
进行中（未招募）
1 期
A study in which is investigated if the medicine bortezomib is effective in patients with AL amyloidosisEUCTR2010-021445-42-NLHOVON Foundation50
进行中（未招募）
1 期
Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC) - PADIMACMultiple MyelomaEUCTR2010-021598-35-GBniversity College London120
已完成
2 期
Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCTTopic: National Cancer Research NetworkSubtopic: Haematological OncologyDisease: MyelomaCancerMultiple myelomaISRCTN03381785niversity College London (UK)153
已完成
1 期
Phase I/II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly VRd-21) for relapsed and/or refractory multiple myeloma (Once weekly VRd-21, I/II VRD for MM)Proteasome inhibitor and immunomodulatory drug pre-treated relapsed and/or refractory multiple myeloma after two or more prior lines of chemotherapyJPRN-UMIN000013169agoya City University Hospital30